Novartis Ceo Joe Jimenez: Technology Can Boost Wellness
Earlier this month , Novartis signed a $580 licensing deal ($20 million upfront and $560 million in milestone payments) with Molecular Partners, a Zurich-based bio/pharmaceutical corporation, to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies for oncology. DARPins refer to “designed ankyrin repeat proteins,” which are genetically engineered antibody mimetic proteins usually exhibiting hugely precise and higher-affinity target protein binding. He...
